Conversion surgery for stage IV gastric cancer after third-line immunotherapy: a case report

Conversion surgery for stage IV gastric cancer after third-line immunotherapy: a case report

The 5-year overall survival rate for stage IV gastric cancer is lower than 10%, despite the development of systemic therapy. Conversion surgery has shown to improve survival outcomes in patients with durable clinical response on chemotherapy. We report a clinical case of a patient, who underwent con...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sevindzh F. Evdokimova, Anna L. Kornietskaya, Larisa V. Bolotina, Iliya V. Kolobayev, Alexander A. Fedenko, Andrey D. Kaprin
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Oncology
Subjects:	gastric cancer (GC) gastroesophageal junction (GEJ) immunotherapy conversion surgery pembrolizumab case report
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1494669/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of pembrolizumab in advanced gastric and gastroesophageal junction cancer: a systematic review and meta-analysis
by: Xiaoying Ji, et al.
Published: (2025-03-01)

Fruquintinib and sintilimab plus SOX as perioperative therapy for locally resectable advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase II clinical trial
by: Xiangyu Meng, et al.
Published: (2025-07-01)

Kyoto International Consensus Report on Anatomy, Pathophysiology and Clinical Significance of the Gastroesophageal Junction
by: A. A. Sheptulin, et al.
Published: (2023-12-01)

Influence of the results of international studies on the choice of treatment tactics for unresectable forms of squamous cell carcinoma of the head and neck
by: L. V. Bolotina, et al.
Published: (2020-07-01)

Primary malignant melanoma of the gastroesophageal junction with KIT gene exon 11 mutation
by: Xiaozhuo Gao, et al.
Published: (2024-06-01)

A Canadian algorithm for upper gastrointestinal cancer management
by: Frédéric Lemay, et al.
Published: (2025-04-01)

Eligibility and workload implications of adjuvant immunotherapy in patients with resected esophageal and gastroesophageal junction (ESO/GEJ) cancer
by: T.H. Lee, et al.
Published: (2025-03-01)

Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy
by: Yan Zhang, et al.
Published: (2025-12-01)

Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2–positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trialResearch in context
by: Zhi Peng, et al.
Published: (2025-09-01)

A case report and analysis of skin metastasis of adenocarcinoma of gastroesophageal junction and its therapeutic outcome
by: LI Hao, DENG Jin, LIU Peihua, ZHANG Quanyong, CAI Zhai
Published: (2025-06-01)

Clinicopathological features and outcome for neuroendocrine neoplasms of gastroesophageal junction: A population‐based study
by: Panpan Zhang, et al.
Published: (2018-09-01)

Case report: Chemotherapy plus sintilimab for the treatment of gastroesophageal junction hepatoid adenocarcinoma with liver metastasis: a case study with literature review
by: Genlin Lu, et al.
Published: (2025-01-01)

Evaluation of Conventional Treatment Planning Techniques for Radiotherapy of Gastroesophageal Junction Cancer: A Dosimetric Comparison between Male and Female Patients
by: Mohamad Pursamimi, et al.
Published: (2025-03-01)

A conceptual model for advanced/metastatic gastric or gastroesophageal junction cancer: a review of qualitative studies and results from patient interviews
by: France Ginchereau Sowell, et al.
Published: (2025-01-01)

Total neoadjuvant chemotherapy according to the FOLFIRINOX regimen for locally advanced adenocarcinoma of the stomach and cardioesophageal junction: interim results
by: M. V. Sedova, et al.
Published: (2023-09-01)

Gastroesophageal reflux disease in patients with morbid obesity
by: A. S. Lavryk, et al.
Published: (2022-02-01)

Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy
by: Huanhuan Li, et al.
Published: (2025-02-01)

Rare clinical observation of pronounced response to immunotherapy in a patient with anaplastic thyroid cancer
by: D. M. Vontlaya, et al.
Published: (2024-06-01)

Immunotherapy in patients with cervical cancer
by: A. G. Kedrova
Published: (2020-11-01)

Evaluating survival outcomes and treatment recommendations in resectable gastric cancer
by: Saad Sabbagh, et al.
Published: (2025-01-01)

Efficacy and safety of Nivolumab in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized controlled trials
by: Xinming Lei, et al.
Published: (2024-11-01)

First-line immune checkpoint inhibitors with chemotherapy in advanced gastric and gastroesophageal junction adenocarcinoma: a meta-analysis of phase 3 trials
by: Yuxuan Lin, et al.
Published: (2025-05-01)

Surgical resection due to poor outcome of the immunotherapy of a relapsed mediastinal liposarcoma: a case report
by: Ming-Ji Wang, et al.
Published: (2023-10-01)

The Role of Diet and Nutrition in Cancer Development and Management: From Molecular Mechanisms to Personalized Interventions
by: Maxim Ruban, et al.
Published: (2025-05-01)

Deciphering the dual role of autophagy in gastric cancer and gastroesophageal junction cancer: from tumor suppression to cancer progression
by: Lili Lei, et al.
Published: (2025-06-01)

Impact of Tregs on tumor regression in locally advanced G/GEJ cancer patients undergoing neoadjuvant chemoimmunotherapy
by: Yong Zhang, et al.
Published: (2025-08-01)

Comparison of the safety of esophagojejunal overlap and π-shaped anastomosis in totally laparoscopic total gastrectomy
by: Tongkun Song, et al.
Published: (2025-01-01)

Laparoscopic curative resection following perioperative chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel and its influence on Claudin18.2 expression in advanced gastric or gastroesophageal junction adenocarcinoma: a two-case report
by: Tohru Takahashi, et al.
Published: (2025-04-01)

Modern possibilities of using immunotherapy in the treatment of cervical cancer
by: A. V. Tarasova, et al.
Published: (2021-09-01)

Role of Circulating Tumor DNA in Adapting Immunotherapy Approaches in Breast Cancer
by: Sudhir Kumar, et al.
Published: (2025-06-01)

Correlation between cough and gastroesophageal reflux in children
by: A. V. Burlutskaya, et al.
Published: (2022-09-01)

Neoadjuvant PD-1/PD-L1 inhibitors combined with chemotherapy in gastric cancer and gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis of single-arm studies
by: Jun Leng, et al.
Published: (2025-08-01)

Cost-effective analysis of sugemalimab plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma with PD-L1 CPS ≥5
by: Yalan Zhang, et al.
Published: (2025-08-01)

Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It
by: Magdalena K. Zielińska, et al.
Published: (2025-02-01)

Use of combined chemotherapy and immunotherapy improves pulmonary arterial hypertension
by: Tejaswini P. Reddy, et al.
Published: (2024-07-01)

Cadonilimab in combination with chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis
by: Zuojuan Xiang, et al.
Published: (2025-07-01)

DNA methylation markers for sensitive detection of circulating tumor DNA in patients with gastroesophageal cancers
by: N. Øgaard, et al.
Published: (2024-12-01)

Cost-effectiveness analysis of first-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma
by: Zhifeng Zhou, et al.
Published: (2025-05-01)

First-line chemotherapy for head and neck squamous cell carcinoma. Optimal strategy
by: L. V. Bolotina, et al.
Published: (2019-01-01)

Maxillary osteonecrosis linked to Pembrolizumab therapy: a case report
by: Gosselin-Rousselle Louise, et al.
Published: (2024-01-01)